Search

In recent years, pollution stemming from pharmaceuticals has garnered widespread global concern, which exacerbates the ecological risk to both surface and groundwater. In the current study, Fe and O co-embedded biochar (Fe-O-BC) was synthesized through a one-step pyrolysis procedure with corncob serving as the feedstock. The fabricated Fe-O-BC catalysts were characterized by various techniques and were employed for the activation of peroxymonosulfate (PMS) to degrade tetracycline (TC). TC was rapidly degraded within 40 min, with a degradation rate of 0.1225 min−1, which was much higher than those for O-BC/PMS (0.0228 min−1) and Fe-BC/PMS (0.0271 min−1) under the same conditions. The effects of PMS dosage, Fe-O-BC dose, initial pH value and coexisting anions for TC degradation were investigated. Finally, the mechanism of TC oxidation in the catalytic system was implored through experiments of determining the active sites and radical scavenging experiments. The C-O-Fe bond in the catalyst was confirmed to be the dominant active sites accelerating TC degradation. Free diffused HO•, the surface-bound HO• and SO4•− and O2•−participated in the reaction and absorbed SO4•−, and HO• predominantly contributed to TC degradation. This study provides an efficient and green alternative for pharmaceutical wastewater treatment by Fe and O co-doped catalyst-induced heterogeneous process. [ABSTRACT FROM AUTHOR]

RIPK1 plays a key role in necroptosis and is associated with various inflammatory diseases. Using structure‐based virtual screening, a novel hit with 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole scaffold was identified as an RIPK1 inhibitor with an IC50 value of 1.3 μM. Further structure–activity relationship study was performed based on similarity research and biological evaluation. The molecular dynamics simulation of compound 2 with RIPK1 indicated that it may act as a type II kinase inhibitor. This study provides a highly efficient way to discover novel scaffold RIPK1 inhibitors for further development. [ABSTRACT FROM AUTHOR]